Definium Therapeutics (DFTX) Free Cash Flow (2021 - 2026)
Definium Therapeutics (DFTX) posted quarterly Free Cash Flow of -$42.5 million for Q1 2026, down 44.46% year-over-year from -$76.5 million in Q1 2025, and up 1.04% quarter-over-quarter from -$43.0 million in Q4 2025.
Definium Therapeutics (DFTX) Free Cash Flow (2021 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Free Cash Flow for 6 consecutive years, with -$42.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 44.46% year-over-year to -$42.5 million; the TTM figure through Mar 2026 stood at -$144.6 million (down 57.23% YoY), while the FY2025 annual figure was -$131.5 million, down 66.32% from the prior year.
- Free Cash Flow grew to -$42.5 million in Q1 2026 per DFTX's latest filing, from -$43.0 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$9.3 million in Q3 2022 and bottomed at -$43.0 million in Q4 2025.
- Historically, Free Cash Flow has averaged -$21.6 million across 5 years, with a median of -$17.2 million in 2024.
- Annual changes were most pronounced in 2022 — Free Cash Flow surged 44.6% — and 2023, when it slumped 78.56%.
- Definium Therapeutics' Free Cash Flow stood at -$12.8 million in 2022, then plunged by 60.11% to -$20.6 million in 2023, then retreated by 23.56% to -$25.4 million in 2024, then slumped by 69.01% to -$43.0 million in 2025, then gained by 1.04% to -$42.5 million in 2026.
- Business Quant data shows DFTX's Free Cash Flow at -$42.5 million in Q1 2026, -$43.0 million in Q4 2025, and -$29.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Definium Therapeutics | 4.72 Bn | 4.72 Bn | - | -52.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -52.91 Mn |
| Jun 30, 2026 | -52.91 Mn |
| Mar 31, 2026 | -42.51 Mn |
| Mar 31, 2026 | -42.51 Mn |
| Dec 31, 2025 | -42.96 Mn |
| Dec 31, 2025 | -42.96 Mn |
| Sep 30, 2025 | -29.56 Mn |
| Sep 30, 2025 | -29.56 Mn |
| Jun 30, 2025 | -29.59 Mn |
| Jun 30, 2025 | -29.59 Mn |
| Mar 31, 2025 | -29.43 Mn |
| Mar 31, 2025 | -29.43 Mn |
| Dec 31, 2024 | -25.42 Mn |
| Dec 31, 2024 | -25.42 Mn |
| Sep 30, 2024 | -17.17 Mn |
| Sep 30, 2024 | -17.17 Mn |
| Jun 30, 2024 | -19.97 Mn |
| Jun 30, 2024 | -19.97 Mn |
| Mar 31, 2024 | -16.53 Mn |
| Mar 31, 2024 | -16.53 Mn |